围手术期枸橼酸西地那非给药在肝切除术中的应用:一项随机对照试验的研究方案
本方案为双盲随机对照试验,拟纳入符合开腹或腹腔镜肝切除术指征的患者,随机分为西地那非(S)组与安慰剂(C)组,评估围手术期枸橼酸西地那非联合间歇性Pringle maneuver对术中出血量、术野及安全性的影响。主要结局为术中出血量,次要结局涵盖术野分级、硝酸甘油累积用量、血流动力学、血气分析、凝血功能、术后住院时间及并发症等。
要点
- 探讨枸橼酸西地那非联合间歇性Pringle maneuver能否减少肝切除术术中出血量。
- 采用双盲、随机、对照设计,通过区组随机化分为西地那非(S)组与安慰剂(C)组。
- 主要结局为术中出血量,次要结局包括术野分级、血流动力学、凝血功能及术后并发症等。
核心结论
- 该试验评估枸橼酸西地那非联合间歇性Pringle maneuver对开腹或腹腔镜肝切除术术中出血量、手术结果及安全性、可行性的影响。
- 作者预期该方案可为减少肝切除术出血提供创新的管理优化方案,并为枸橼酸西地那非或类似药物改善围手术期肝切除患者安全与质量的潜在价值提供经验支持。
研究设计与样本
- 本研究为双盲、随机、对照试验,所有符合开腹或腹腔镜肝切除术标准的患者通过区组随机化方法随机分配至西地那非(S)组和安慰剂(C)组。
- 所有外科医生、麻醉医生和结局评估者对患者的组别信息保持盲态。
- 该试验于2024年6月25日在美国临床试验注册中心注册,ClinicalTrials.gov标识符为NCT06237751,方案版本为V1.0(20,231,114)。
主要发现
- 主要结局为术中出血量。
- 次要结局包括术野分级、硝酸甘油累积用量、血流动力学参数、血气分析、凝血功能(包括血栓弹力图、活化部分凝血活酶时间和凝血酶原时间)、术中尿量、恢复室不良事件(低血压、低氧血症和血尿)、生化标志物(总胆红素、总白蛋白、丙氨酸氨基转移酶、天冬氨酸氨基转移酶、肌酐、尿素氮)、全血细胞计数(Hb、Plt和Hct)、心功能(脑钠肽、肌酸激酶同工酶、肌钙蛋白)、术后住院时间和引流管留置时间以及术后并发症。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Intraoperative blood loss (IBL) is the major concern in hepatectomy, which was closely relating to the central venous pressure (CVP). The controlled low central venous pressure (CLCVP) technique is moderately required for minimizing hemorrhage during hepatectomy nowadays. Nevertheless, an excessive reduction in CVP might give rise to the jeopardy of inadequate perfusion of vital organs. Sildenafil, being a first-line pharmaceutical for treating pulmonary hypertension, its mechanism of action lies in diminishing pulmonary vascular resistance (PVR) by dilating pulmonary arteries, and thereby alleviating the afterload of the right ventricle. We initially postulate that administration of sildenafil citrate in combination with intermittent Pringle's maneuver (IPM) can exert a notable impact in efficaciously reducing intraoperative blood loss (IBL), enhancing the surgical field of vision, and augmenting the safety of the operation. METHODS: This research constitutes a double-blind, randomized, controlled trial. All patients fulfilling the criteria for open or laparoscopic hepatectomy will be randomly allocated to the sildenafil (S) group and the placebo (C) group via the block randomization approach. All surgeons, anesthesiologists, and outcome assessors will remain oblivious to the patient's group details. The primary outcome is the intraoperative blood loss (IBL). Secondary outcomes include the classification of the surgical field, the cumulative consumption of nitroglycerine, hemodynamic parameters, blood gas analysis, coagulation function (comprising thromboelastogram (TEG), activated partial thromboplastin time (APTT), and prothrombin time (PT)), intraoperative urine output, adverse events in the recovery room (hypotension, hypoxemia and hematuria), biochemical markers (total bilirubin, total albumin, alanine aminotransferase, aspartate aminotransferase, creatinine, urea nitrogen), complete blood count (Hb, Plt, and Hct), cardiac function (brain natriuretic peptide, creatine kinase isoenzyme, troponin), postoperative hospital stay and indwelling time of drainage tube, and postoperative complications. These parameters will be comprehensively compared and analyzed in-depth through appropriate statistical means. DISCUSSION: This trial evaluated the influence of administration of sildenafil citrate combined with IPM on IBL and surgical results during open or laparoscopic hepatectomy, as well as its safety and feasibility. It is expected to provide an innovative management optimization plan for reducing the bleeding in hepatectomy, and to provide empirical support for the potential value of sildenafil citrate or sildenafil-like drugs in improving the safety and quality of perioperative hepatectomy patients. TRIAL REGISTRATION: This trial was registered on June 25, 2024, in the US Clinical Trials Registry ( https://register. CLINICALTRIALS: gov ), with the ClinicalTrial.gov Identifier: NCT06237751. The protocol version is V1.0 (20,231,114).
引用
- Chen Q, Peng S, Zhou Y, et al. Perioperative sildenafil citrate administration in hepatectomy: a study protocol of randomized controlled trial. Trials. 2025. PMID: 40450350. doi:10.1186/s13063-025-08870-2
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。